Akari Therapeutics Ownership
| AKTX Stock | USD 1.21 0.09 8.04% |
Shares in Circulation | First Issued 2014-03-31 | Previous Quarter 9.4 M | Current Value 12.2 M | Avarage Shares Outstanding 9.6 M | Quarterly Volatility 16 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Akari |
Akari Stock Ownership Analysis
The company recorded a loss per share of 2.58. Akari Therapeutics PLC had not issued any dividends in recent years. The entity had 1:20 split on the 17th of August 2023. Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Akari Therapeutics, Plc is based in London, the United Kingdom. Akari Therapeutics is traded on NASDAQ Exchange in the United States. For more info on Akari Therapeutics PLC please contact Samir MD at 929 274 7510 or go to https://www.akaritx.com.Besides selling stocks to institutional investors, Akari Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Akari Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Akari Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Akari Therapeutics Quarterly Liabilities And Stockholders Equity |
|
About 12.0% of Akari Therapeutics PLC are currently held by insiders. Unlike Akari Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Akari Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Akari Therapeutics' insider trades
Akari Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Akari Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Akari Therapeutics PLC backward and forwards among themselves. Akari Therapeutics' institutional investor refers to the entity that pools money to purchase Akari Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Sabby Management Llc | 2024-06-30 | 0.0 | Truvestments Capital Llc | 2024-06-30 | 0.0 | Omnia Family Wealth, Llc | 2024-06-30 | 87.6 K | Citadel Advisors Llc | 2024-09-30 | 33.3 K | Hpm Partners Llc | 2024-06-30 | 23.6 K | Cresset Asset Management, Llc | 2024-09-30 | 18.4 K | Renaissance Technologies Corp | 2024-09-30 | 18.1 K | Susquehanna International Group, Llp | 2024-06-30 | 17.2 K | Ubs Group Ag | 2024-06-30 | 16 K | Bank Of America Corp | 2024-06-30 | 150 | Advisor Group Holdings, Inc. | 2024-06-30 | 100.0 |
Akari Therapeutics PLC Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Akari Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Akari Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Akari Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Akari Therapeutics Outstanding Bonds
Akari Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Akari Therapeutics PLC uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Akari bonds can be classified according to their maturity, which is the date when Akari Therapeutics PLC has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Akari Stock Analysis
When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.